top of page

2024 Abstract Posters

Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Using artificial intelligence to identify patient characteristics associated with rapid fibrosis progression in NASH: a retrospective cohort study

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

When to Intervene? Onset and Timing of Obesity-related Metabolic Derangements After Liver Transplant

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MIRICORILANT IN ADULT PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS/METABOLIC DYSFUNCTION-ASSOCIATED
STEATOHEPATITIS (NASH/MASH)

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

The Effects of a Combined Exercise Interventionon Gut Microbiomes and Systemic InflammatoryBiomarkers in MASLD Patients: A Study Protocol

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

The Disease Severity Index from HepQuant DuO and Likelihood for Large Esophageal Varices in the
SHUNT V Study

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

The NEXT GENERATION HepQuant Tests Measure Reduction in Risk for Clinical Events in Compensated NASH Cirrhosis Subjects Treated with Resmetirom

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Imaging in Chronic Liver Disease: A Comparative Analysis Using Magnetic Resonance Elastography and Multiparametric Magnetic
Resonance Imaging

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

FIBROSIS DISTRIBUTION IN LEAN VERSUS OBESE NASH-CIRRHOSIS PATIENTS USING SHG/TPE MICROSCOPY

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Performance of novel collagen turnover biomarkers in comparison to FIB-4 to detect increased liver stiffness in MASLD

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Characterizing the management of patients with NASH (with versus without cirrhosis) in real-world clinical practice –Low utilization of gastroenterology and hepatology specialty care

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

A longitudinal assessment of cardiovascular risk for
NASH/MASH patients enrolled in TARGET-NASH

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Comparing cardiovascular and infection complications in liver transplant patients with NASH vs other indications

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Targeting EF-hand domain family member D1 (EFHD1) in liver disease

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Lysophosphatidic acid receptor 1 antagonist (EPGN2154) improves murine MASH.

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

ORAL αvβ6/αvβ1 INTEGRIN INHIBITION IN PRIMARY SCLEROSING CHOLANGITIS: 12-WEEK INTERIM SAFETY AND EFFICACY ANALYSIS OF INTEGRIS-PSC, A PHASE 2A TRIAL OF BEXOTEGRAST

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Postprandial plasma proteomics in metabolic dysfunction-associated
steatotic liver disease

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Higher FIB-4 is associated with higher clinical and economic burden of CV events in non-cirrhotic NASH

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Enhancing ASCVD Risk Prediction in NASH/NAFLD Patients

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

The small molecule competitive inhibitor of ATP citrate lyase, EVT0185, reverses liver fibrosis in preclinical mouse models by targeting hepatic stellate cells

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

PLN-1474, AN ORAL, SELECTIVE αvβ1 INTEGRIN INHIBITOR, IS WELL TOLERATED IN HEALTHY VOLUNTEERS

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Miricorilant reduced liver fat and cardiometabolic disease
markers in a phase 1b, open-label dose-finding study in
patients with non-alcoholic steatohepatitis (NASH)

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Barriers to and opportunities for improved MASLD/MASH education: a qualitative discussion with medical training program leaders

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic MASLD

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Is it fatty liver or fatty pancreas have more cvs affection and why

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Next Generation HepQuant Tests for the Clinic and Clinical Trials: Within
Individual Reproducibility
and Diagnostic Performance for Large Esophageal Varices

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Stratifying Disease Severity and Predicting Risk for Clinical Decompensation in Primary Sclerosing
Cholangitis: Results with Next Generation HepQuant Tests

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Comparison of costs and referral rates of non-invasive testing strategies for metabolic dysfunction-associated steatohepatitis (MASH) in a Veteran population

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

THE PERFORMANCE OF VELACUR AGAINST LIVER BIOPSY FOR ASSESSING FIBROSIS AND STEATOSIS

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Non-invasive tests as a prediction tool to assess MASH resolution score

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

LIVERFASt (L-FAST) identifies advanced (F3F4, AF) and clinically significant fibrosis (F2-F4, CSF) especially well with Fibroscan in MASLD patients (pts) from a tertiary hepatology center.

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Characterizing the real-world clinical outcomes of patients with NASH without cirrhosis versus with cirrhosis

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Deploying a Consensus Metabolic Dysfunction-Associated Steatohepatitis (MASH) Care Pathway and Educational Pilot in Three U.S. Health Systems

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Semaglutide and lanifibranor differentially alter MASH and liver fibrosis in diet-induced obese hamsters with or without free access to alcohol

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Preclinical characterization of bi-functional NK-aHSC engager for liver fibrosis

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Lanifibranor Reverses Hepatic and Peripheral Insulin Resistance, Improves Lipid and Glucose Metabolism in Patients with
Type 2 Diabetes (T2D) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Inhibition of integrin αVβ1 attenuates profibrogenic gene expression by myofibroblasts in fibrotic human liver explants

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

The crosslinked type III collagen biomarker, CTX III, reflects fibrosis resolution and is related to intervention and survival in chronic liver disease

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Enhancing ASCVD Risk Prediction in NASH/NAFLD Patients

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Low Immunogenicity Rates in Phenotypic MASH Patients
Treated for 12 Weeks With Once-monthly and Bi-weekly
Subcutaneous Dosing of BOS-580

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Improvements in Liver Fibroinflammation(as assessed by Corrected T1 [cT1]) with HTD1801 (Berberine Ursodeoxycholate) Treatment in Patients with Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

HEPATIC FUNCTIONAL IMPROVEMENT DETECTED BY HEPQUANT DUO WITHIN 120 DAYS OF TREATMENT WITH RENCOFILSTAT (RCF) IN MASH SUBJECTS WITH ≥ F3 FIBROSIS

Click Here
Abstract #1_Poster NASH-TAG 2022__Draft 3.jpg

Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease Correlates with Improvements in Non-Invasive Markers of Inflammation and Fibrosis: Results of a 24-Week Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Click Here
bottom of page